Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Transcriptome Signature Reversion as a Method to Reposition Drugs Against Cancer for Precision Oncology

Koudijs, Karel K. M., PharmD*; Terwisscha van Scheltinga, Anton G. T., PharmD, PhD*; Böhringer, Stefan, MD, PhD; Schimmel, Kirsten J. M., PharmD, PhD*; Guchelaar, Henk-Jan, PharmD, PhD

doi: 10.1097/PPO.0000000000000370
Review Articles
Buy
SDC

Transcriptome signature reversion (TSR) has been hypothesized as a promising method for discovery and use of existing noncancer drugs as potential drugs in the treatment of cancer (i.e., drug repositioning, drug repurposing). The TSR assumes that drugs with the ability to revert the gene expression associated with a diseased state back to its healthy state are potentially therapeutic candidates for that disease. This article reviews methodology of TSR and critically discusses key TSR studies. In addition, potential conceptual and computational improvements of this novel methodology are discussed as well as its current and possible future application in precision oncology trials.

From the Departments of *Clinical Pharmacy & Toxicology and

Medical Statistics, Leiden University Medical Centre, Leiden, the Netherlands.

The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.

Reprints: Henk-Jan Guchelaar, PharmD, PhD, Post-Office Box, 9600 2300 RC, Leiden Postzone L0-P, the Netherlands. E-mail: h.j.guchelaar@lumc.nl.

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.